Literature DB >> 2212768

[Studies on Chlamydia pneumoniae, strain TWAR infection. 2. Seroepidemiology of TWAR on healthy controls and patients with acute respiratory infections].

T Kishimoto1.   

Abstract

To determine of Chlamydia pneumoniae, TWAR infection is common in Japan. The author performed a spot antibody prevalence study of adults and children living in Okayama prefecture. This study was carried out by microplate immunofluorescence antibody technique (MFA) using in situ inclusions of Chlamydia pneumoniae (TW-183), Chlamydia trachomatis (L2) and Chlamydia psittaci (Cal 10) as antigens respectively. And each chlamydial antiserum IgG, IgA, IgM titers were determined by the dilution and point for specific staining of the inclusions. The author studied people with and without evidence of acute respiratory infections, as determined by physical examination and medical history. 2050 sera of 1477 cases were collected from both groups between 1987 and 1989. The criteria for judgement the positivity of antibodies to chlamydia species are as follows: By comparing the IgG antibody titers determined with different chlamydia antigen, a case was regarded as having an antibody specific to a particular chlamydia species when the titer was highest for that strain and the titer was greater than x 64. In cases which blood was collected more than once, the point in time at which IgG showed the highest titer was used. TWAR specific antibody was detected to be 52/143 cases (36.4%) of healthy children (age 0-15) and 319/531 cases (60.1%) of healthy adults (age 16-85). It was also detected to be 134/478 cases (27.9%) of child patients with acute respiratory infections (age 0-15), and 231/325 cases (71.1%) of adult patients (age 16-95).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2212768     DOI: 10.11150/kansenshogakuzasshi1970.64.986

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  2 in total

1.  Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland.

Authors:  Mika Paldanius; Aini Bloigu; Marianne Alho; Maija Leinonen; Pekka Saikku
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

2.  In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors:  M Kimura; T Kishimoto; Y Niki; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.